Tinostamustine Enters Phase 1/2 Trial to Treat Ovarian Cancer, Other Solid Tumors

Tinostamustine Enters Phase 1/2 Trial to Treat Ovarian Cancer, Other Solid Tumors
The investigational medicine tinostamustine (EDO-S101), developed by Mundipharma EDO GmbH, is now being tested in patients with advanced solid tumors, including ovarian cancer, in a first-in-human Phase 1/2 clinical trial. The trial will assess the safety, tolerability, and effectiveness of the new treatment in participants recruited at Stanford University, Cedars Sinai Medical Center in Los

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *